(ISRs). Among the 15,239 shots administered, 63.4% of the lenacapavir recipients reported subcutaneous nodules, while 56.4% ...

Lenacapavir showed a 96% reduction in HIV infections, outperforming daily F/TDF in the PURPOSE 2 trial. The trial included a diverse global population, with 67% non-White participants, enhancing ...

Gilead Sciences has refiled for FDA approval of its HIV capsid inhibitor lenacapavir – which only needs to be dosed every six months – after the drug was rejected by the regulator in February.

Lenacapavir (previously GS-6207) is the first in a new class of class HIV-1 capsid inhibitor that Gilead is hoping will eventually free patients from the need to take daily oral tablets, although ...

(RTTNews) - Gilead Sciences Inc. (GILD) announced that additional data from its pivotal Phase 3 PURPOSE 2 trial demonstrated a 96% reduction in HIV infections with Lenacapavir compared to the ...

Gilead Sciences, Inc. GILD recently announced additional efficacy, safety and demographic data from its late-stage study on lenacapavir, a twice-yearly injectable HIV-1 capsid inhibitor ...

Along with these most recent study results, the potent antiviral activities, and pharmacokinetic profiles of islatravir and lenacapavir support their continued development as an investigational ...

Nodules occur because lenacapavir is injected under the skin where it forms a drug depot. Injection site reactions and nodule ...

A bi-annual injectable treatment for HIV prevention (PrEP), Lenacapavir, is being celebrated as a major advancement in the field. This followed new study results that showed a 96 per cent ...

Twenty-nine people dropped out of the study because of these, 26 in the lenacapavir arm and three in the prevention pill arm (people in this study arm received placebo jabs). The most common injection ...